Thank you, Mr. Chair.
As president of the Canadian Institutes of Health Research, or CIHR for short, it is my pleasure to address this committee and apprise the committee of some of our recent activities that are helping drive innovations in health care.
As I am sure you are aware, CIHR is the Government of Canada's agency responsible for supporting all sectors of health research, from biomedicine to social determinants of health.
Our mandate is not only to support the creation of new knowledge, but also to ensure that this knowledge is translated into practice in order to improve health services and products, and, in turn, the health of Canadians. In other words, we are ensuring the social and clinical impacts of health research, and stimulating health innovation.
This is achieved through investments in two types of research projects. The first type of projects are investigator-initiated, as they are spurred by the curiosity of researchers. They account for approximately 70% of CIHR's annual budget. The remaining 30% are priority-driven projects, which respond to emerging threats such as Ebola or H1N1; major societal issues such as obesity or dementia; or emerging opportunities in health innovation, such as big data and personalized medicine.
In your review of the supplementary estimates (A), you will see that CIHR has requested the funding allocated through budget 2015, which will advance health research into two priority areas for Canada. The first is in the area of clinical trials, a cornerstone of evidence-based practice, and a critical step for determining which intervention, drug, or diagnostic procedure works, and for whom.
A new investment of $13 million a year, announced through budget 2015, will be allocated toward a major new initiative aimed at developing innovative approaches to the conduct of clinical trials in Canada. This innovative clinical trials initiative is part of Canada's strategy for patient-oriented research, or SPOR, a broader program developed in partnership with the provinces and the territories as well as with charitable and private sectors, to bring health innovations to the bedside and share best practices across the various jurisdictions in the country.
Through its innovative clinical trials initiative, CIHR will fund researchers to develop and adopt innovative methods for carrying out clinical trials as alternatives to traditional randomized control trials. Developing new and innovative methods for clinical trials will offer the possibility to test interventions, drugs, and practices in the real world as opposed to narrowly selected population samples, and to take advantage of the provinces exceptional data banks through emerging big data analytics. Through this initiative, we hope to stimulate the development of new approaches aimed at reducing the cost of conducting trials, at reducing the amount of time needed to answer research questions, and at increasing the relevance of research findings to patients, health care providers, and policy-makers.
The second area where CIHR is driving innovation in health is in antimicrobial resistance, or AMR. Increasingly over the last few years, AMR has been recognized internationally as an emerging health crisis that threatens to undermine our ability to control bacterial infections.
As you know, antimicrobial resistance results from the adaptation of microorganisms to antimicrobial medicine, which allows it to counter the effects. The evolution of resistant strains is a natural phenomenon that has always occurred; however, we are now seeing a disturbing acceleration of this phenomenon due to misuse in animal farming, veterinary medicine and clinical use among humans.
If the spread of antimicrobial resistance (AMR) is not checked, and if new methods for treating bacterial infections are not found through research, we face returning to a pre-antibiotic-like era. This would be absolutely devastating and, in some respects, reverse decades of scientific progress.
To put this into perspective, according to a major 2014 study, 300 million people are expected to die prematurely because of drug resistance over the next 35 years. This would lead to a decrease in the world's GDP of between $60 trillion U.S. and $100 trillion U.S.
CIHR has identified AMR as a research priority for over 10 years, and has launched a number of strategic initiatives in this area to better understand and address the health challenges posed by antimicrobial resistant infections, including the development of alternatives to antibiotics, such as phage or monoclonal antibody approaches. Many of these initiatives are being carried out in collaboration with international partners, notably, the European Commission, with which CIHR co-directs a research funding initiative.
The additional $2 million per year allocation provided through budget 2015, which will be further leveraged through a one-to-one matching from private sector partners, will be devoted to supporting research aimed at developing, evaluating, or implementing point-of-care diagnostic tools to improve appropriate identification and, therefore, treatment of microbial infections.
Through targeted initiatives, like the two initiatives I have described today, CIHR is building and mobilizing Canada's research capacity to address critical health issues and opportunities in health. These efforts aim to maximize the collective efforts of the many players in the Canadian health research enterprise to unlock resources and reap the benefits of our joint investments.
Thank you, Mr. Chair.